Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
about
Cancer stem cells: a systems biology view of their role in prognosis and therapyInhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenHistones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification.FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer PatientsAn apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells'BRCAness' and its implications for platinum action in gynecologic cancer.Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenThe effect of salinomycin on ovarian cancer stem-like cells.Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.New developments in the treatment of ovarian cancer--future perspectives.Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.Is serum level of nestin useful in detecting epithelial ovarian cancer?The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.Ovarian cancer stem cells: a new target for cancer therapy.The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.Clinical Impact of microRNAs Associated With Cancer Stem Cells as a Prognostic Factor in Ovarian Carcinoma.Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical studyCharacterization of stem cell and cancer stem cell populations in ovary and ovarian tumors
P2860
Q33569712-4FA53CD8-DC2F-4904-B321-874939AFE8AFQ33628532-6C431509-0040-4BD5-9257-1FEE51159BFFQ33741828-3B98A211-3D81-49FE-AB69-C12D3D8EC876Q33890763-18F716A4-5D8A-4211-9615-C7CB46EA53BCQ35248417-7AA2D976-8482-43E7-8184-8510E5B39620Q35273654-9368A385-4CB0-40B0-BB94-E11DED3862D6Q35650181-B2EB1ADF-A593-497B-B606-4CC429AB9626Q35844366-0425D41D-56B3-4F77-8CC3-B6FA941B7C4FQ35941858-F37DCA81-3BA7-4345-B8BF-0B43A6E2AD44Q36070842-0921C514-ED4D-4AE9-8B72-9108F9DFC242Q36265840-12D627C7-29FE-45DE-9044-E4279BA363F1Q36380704-5DA6A135-7E9B-4472-AE94-7B0DB921C3A4Q36414274-DB885E48-9CA5-4CB4-A052-410F9353CD22Q36761363-E3AE7B47-006F-4E69-AEFD-660149BAD7C1Q36891437-02ACC4C3-DE90-45EE-9C67-53A629DD143BQ37121113-39B5A9EA-49C8-4084-96AA-7193805CFABCQ37196532-E0921C52-A951-451F-BA5E-134659CE4DAFQ37332487-E923809F-EA17-47D6-95FB-C893F1CB7420Q37532147-0AA33B30-CBAA-423B-9FA7-FA6B4FE25597Q37705457-E30FBF36-4B28-4A91-A0E8-50EBFECAF52CQ37708778-DCB1D587-4DD3-47C3-A83E-149427184EEAQ38705370-58D6C129-BDFA-4336-A271-FED348780289Q38849720-823F28A4-332C-4476-AFAB-83A8E04EB034Q39084693-768869C4-C6A1-4EFF-BC72-2E1EBF646384Q41279960-D0D0C38D-9F3A-4BF1-961A-9F521BC8D7DBQ41848132-D390ACBF-D03E-4AA1-AA43-567681A06C5DQ42092160-10EF7A5E-FDC1-4B76-8FD8-6210D10AA5AFQ44301485-8C499969-C213-48A6-AB5D-323E72BC46B7Q45612220-227FABB8-8B9E-4537-8599-C91A823A93C5Q54114902-3804C9C8-E223-45F8-9F81-278E2DE69359Q58712023-F64E67DE-B6A6-4DC8-A9D0-ADE3392529ADQ58766995-54247E54-D9E2-49DD-B413-78F2EC312229
P2860
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancerous ovarian stem cells: ...... t relevant to chemoresistance.
@en
type
label
Cancerous ovarian stem cells: ...... t relevant to chemoresistance.
@en
prefLabel
Cancerous ovarian stem cells: ...... t relevant to chemoresistance.
@en
P2093
P2860
P356
P1476
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance
@en
P2093
Jock Findlay
Khalid Abubaker
Nuzhat Ahmed
P2860
P356
10.1002/JCB.24317
P577
2013-01-01T00:00:00Z